Trial in progress: A phase 1 study of KTX-1001, an oral, first-in-class, selective MMSET inhibitor in patients with relapsed and refractory multiple myeloma Meeting Abstract
| Authors: | Berdeja, J. G.; Dingli, D.; Lonial, S.; Yee, A. J.; Chung, A.; Gasparetto, C.; Bergsagel, P. L.; Roy, V.; Abdallah, A. O.; Thanendrarajan, S.; Afrough, A.; Rosiñol, L.; Trudel, S.; Otero, P. R.; Touzeau, C.; Bories, P.; Bang, S.; Connolly, T.; Kim, M.; Lewis, C. A.; Linberg, B. V. T.; Quigley, M. T.; Landgren, O.; Usmani, S. Z.; Mateos, M. V.; Siegel, D. S. |
| Abstract Title: | Trial in progress: A phase 1 study of KTX-1001, an oral, first-in-class, selective MMSET inhibitor in patients with relapsed and refractory multiple myeloma |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 3391 |
| Language: | English |
| ACCESSION: | WOS:001159740304002 |
| DOI: | 10.1182/blood-2023-174550 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
